Production (Stage)
Emergent BioSolutions Inc.
EBS
$6.40
-$0.10-1.54%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 222.20M | 194.70M | 293.80M | 254.70M | 300.40M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 222.20M | 194.70M | 293.80M | 254.70M | 300.40M |
| Cost of Revenue | 102.80M | 58.20M | 129.60M | 320.20M | 159.60M |
| Gross Profit | 119.40M | 136.50M | 164.20M | -65.50M | 140.80M |
| SG&A Expenses | 52.70M | 60.70M | 75.90M | 77.30M | 84.80M |
| Depreciation & Amortization | 16.30M | 16.30M | 16.30M | 16.30M | 16.20M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 171.80M | 199.00M | 221.80M | 413.80M | 260.60M |
| Operating Income | 50.40M | -4.30M | 72.00M | -159.10M | 39.80M |
| Income Before Tax | 92.70M | -27.60M | 142.40M | -269.80M | 12.10M |
| Income Tax Expenses | 24.70M | 3.70M | 27.60M | 13.30M | 3.10M |
| Earnings from Continuing Operations | 68.00M | -31.30M | 114.80M | -283.10M | 9.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.00M | -31.30M | 114.80M | -283.10M | 9.00M |
| EBIT | 50.40M | -4.30M | 72.00M | -159.10M | 39.80M |
| EBITDA | 75.20M | 21.00M | 97.70M | -131.50M | 66.80M |
| EPS Basic | 1.25 | -0.58 | 2.16 | -5.38 | 0.17 |
| Normalized Basic EPS | 1.12 | -0.25 | 1.01 | -2.20 | 0.14 |
| EPS Diluted | 1.19 | -0.58 | 2.06 | -5.38 | 0.17 |
| Normalized Diluted EPS | 1.06 | -0.25 | 0.96 | -2.20 | 0.14 |
| Average Basic Shares Outstanding | 54.40M | 54.20M | 53.10M | 52.60M | 52.20M |
| Average Diluted Shares Outstanding | 57.30M | 54.20M | 55.60M | 52.60M | 52.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |